TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Enanta Pharmaceuticals ( (ENTA) ) is now available.
On August 26, 2025, Enanta Pharmaceuticals appointed Harry R. Trout, III as interim principal financial officer and Kathleen S. Capps as interim principal accounting officer during the medical leave of Paul J. Mellett, the Chief Financial and Administrative Officer. This interim leadership change ensures continuity in the company’s financial operations, with both appointees having extensive experience within the company and the industry.
The most recent analyst rating on (ENTA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
Spark’s Take on ENTA Stock
According to Spark, TipRanks’ AI Analyst, ENTA is a Neutral.
Enanta Pharmaceuticals’ overall stock score is primarily influenced by its challenging financial performance and valuation concerns, with a negative P/E ratio and no dividend yield. However, positive technical indicators provide some bullish momentum, and the ongoing legal proceedings against Pfizer introduce both potential upside and significant risk.
To see Spark’s full report on ENTA stock, click here.
More about Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of small molecule drugs for viral infections and liver diseases.
Average Trading Volume: 173,555
Technical Sentiment Signal: Sell
Current Market Cap: $184.9M
For detailed information about ENTA stock, go to TipRanks’ Stock Analysis page.